BEIJING – Fibrogen Inc. said its first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (previously FG-4592) won a second approval in China to include more patients with anemia caused by chronic kidney disease (CKD). China, again, is the first market to grant the company the nod to treat patients who are not dialysis-dependent.